Bronchial carcinoid tumour

Last revised by Liz Silverstone on 24 Sep 2023

Bronchial carcinoid tumours are carcinoid tumours primarily occurring in relation to a bronchus. They were previously incorrectly termed bronchial adenomas. They usually occur in association with a segmental or larger bronchus.

Typically affects patients from the 3rd to 7th decades with the mean age around 45 years 7,10.

The presentation can vary depending on location. Central neoplasms can cause bronchial obstruction and distal pneumonia, atelectasis, bronchiectasis, air-trapping or lung abscess. Partial airway obstruction can cause cough, wheezing and recurrent pulmonary infections. Peripheral tumours are generally asymptomatic and can cause air-trapping. Presentation with carcinoid syndrome is rare (~2-5%) 5,10.

They are neuroendocrine neoplasms that range from low-grade typical carcinoids to more aggressive atypical carcinoids.

Most (~60%) occur centrally within the major bronchi, or rarely within the trachea 4.

Tumours may be seen as filling defects in the main bronchi or trachea with sharp, possibly notched margins 2. Associated airway stenosis with pulmonary atelectasis may be also seen.

Central lesions are usually seen as:

  • a single hilar or perihilar mass that is usually well-defined, round or ovoid

  • can be of any size but are typically 2-5 cm

  • there is often marked homogeneous contrast enhancement due to high vascularity

  • calcification (usually eccentric) can occur but is not a common feature

F18-FDG PET-CT helps to distinguish aggressive tumours: well-differentiated carcinoid tumours ususally show low FDG avidity. FDG avidity is increased in high-grade and poorly differentiated carcinoid tumours 14.

Gallium-68 DOTATATE has shown high accuracy, better imaging quality and lower radiation dose than octreotide scan. Its sensitivity and specificity reaches 80% to 95% as it contains a synthetic somatostatin analogue that has high affinity for somatostatin 2 receptors on the surface membrane of well-differentiated primary and metastatic neuroendocrine tumours 14.

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.